Treatment of Patients With Stage III Non-small Cell Lung Cancer in Russia

Study Overview
=================
Brief Summary
-----------------
In connection with the transition to the 8th version of the classification of lung cancer according to the TNM system, there are currently no precise epidemiological data on stage III NSCLC, clinical characteristics of patients in this group, approaches to therapy and treatment results in the Russian Federation. The published statistics only provide information on the overall incidence of stage III lung, trachea and bronchial cancer, which is about 40%. This observational study will make it possible to characterize the Russian population of stage III non-small cell lung cancer patients, approaches to choosing a treatment option for stage III NSCLC and the outcomes of this treatment in real clinical practice.

Official Title
-----------------
Epidemiology, Approaches to the Diagnosis and Treatment of Patients With Stage III Non-small Cell Lung Cancer in Russia

Conditions
-----------------
Stage III Non-small Cell Lung Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - stage III non-small cell lung cancer Exclusion Criteria: - the rest of the disease stage

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Examine clinical and morphological groups | gender ratio (husband, wife) smoking status (smoker, non-smoker, past smoker) proportional distribution: squamous cell, adenocarcinoma, dimorphic cancer, others) how many patients with mediastinal lymph node involvement: (N0, N1, N2, N3) detection frequency: PDL (PDL <1, PDL> 1, PDL <49, PDL> 50), EGFR (EGFR + (19.24 exon) EGFR-), (ALK +, ALK -), (ROS-1 +, ROS-1 -) Get information about regional algorithms Variants of treatment tactics: Percentage: a. Surgery v. Chemotherapy -Diagnostic algorithm: a. Morphological verification frequency b. The frequency of confirmation of metastatic lesions within the thoracic lymph nodes c. F | 10/01/2023 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Explore clinical approaches | Percentage of treatment options depending on: a. histological type squamous adenocarcinoma dimorphic 3 A st 3B st | 10/01/2023 | 
| Diagnostic algorithm: | v. from a variant of molecular genetic disorders PDL <1 PDL> 1 PDL <49 PDL> 50 EGFR + | 10/01/2023 | 
| Percentage of treatment options | from functional status ECOG 1 only surgical treatment surgical + drug treatment surgical + drug treatment + radiation therapy drug treatment drug treatment + radiation therapy radiation therapy ECOG 2 only surgical treatment surgical + drug treatment surgical + drug treatment + radiation therapy drug treatment drug treatment + radiation therapy radiation therapy ECOG 3 only surgical treatment surgical + drug treatment surgical + drug treatment + radiation therapy drug treatment drug treatment + radiation therapy radiation therapy | 10/01/2023 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
non-small cell lung cancer